STOP PROGRAM EVALUATION

Katherine Heath, PhD

STOP OBJECTIVES

Reduce HIV/AIDS cases - incidence

Improve effectiveness of HIV screening and early detection

Ensure timely access to high-quality and safe HIV care and treatment

Improve patient experience

Demonstrate cost-optimization

CURRENT EVALUATION STRATEGY: MONITORING "INDICATORS"

Quantifiable, objective outcomes that can be assessed at regular intervals to measure the effects of STOP activities

S6 clinical, surveillance, economic, and social

Reflect important goals of STOP

Selected by a technical indicators working group- constant and ongoing evolution to be meaningful

DATA LINKAGE PARTNERSHIPS

BC Centre for Excellence in HIV/AIDS

Treatment history, laboratory outcomes (ex. CD4 at first treatment)

BC Centre for Disease Control

- HIV and other testing data (ex. date of first positive test)
- Ministry of Health-administrative databases
 - MSP billing, Discharge Abstract Database, Mental Health, Addictions,

PharmaNet, Home and Community Care (ex. resource utilization patterns)

Others under negotiation

INDICATOR 14: PROPORTION OF INDIVIDUALS STARTING ART LATE IN THE COURSE OF HIV DISEASE

Definition- the proportion individuals who have cd4 cell counts <200 cells at ART initiation (advanced disease and require immediate therapy)

Goal- decrease

INDICATOR 14: PROPORTION OF INDIVIDUALS STARTING ART LATE IN THE COURSE OF HIV DISEASE



GOOD MEASUREMENT

As provincial roll out begins HSDA will want to know their "baselines" and engage in evaluation of new programs.

Use measures that are:

- Objective an inch is an inch, well and strictly defined
- Consistent an inch is an inch this week and next year, underwater or on the moon
- Comparable your ruler measures an inch the same way as my ruler

WHY SHOULD HSDA PERFORM EVALUATIONS

Provincial level- Assess progress over time towards program goals

Allows valid and reliable comparisons:
 before and after programming changes
 between competing programs
 to other regions or provincial statistics
 Between patient populations

WHY SHOULD HSDA PERFORM EVALUATIONS 2

Feedback to provincial evaluation strategy

Example – 20% of patients starting ARV with CD4<200</p>

- VCH investigates
- Large proportion of individuals diagnoses late!
- Enhanced testing

Development of a HSDA-specific indicator

New indicator for consideration

PARTNERSHIP

- The BC Centre for Excellence in HIV/AIDS is conducting the Provincial level ongoing evaluation and monitoring.
 BCCDC works to monitor the epidemic
 HSDA evaluations should be valid and complimentary
 - Use validated tools- don't re-invent
 - Use STOP indicator standardized definitions- ex. PVL suppression- <200 at 9 months
 - Talk to your partners at the BCCfE and BCCDC for information and expertise

SUMMARY

Only by measuring can we monitor our progress

Evaluation is not an afterthought but part of novel programing

Use valid, reliable previously agreed upon tools for measurement

Engage with BCCfE and BCCDC



Monitoring and evaluation: The role of the BC Centre for Disease Control

Mark Gilbert, MD, MHSc, FRCPC

STOP HIV/AIDS Provincial Expansion Knowledge Kick Off February 1, 2013



Clinical Prevention Services Division

- Provincial surveillance for HIV and AIDS
 - Case report data for new HIV diagnoses, AIDS
 - Conduct provincial analyses of data
 - Acting on behalf of the Provincial Health Officer
 - Also conduct for STIs, TB, Hepatitis B, C (co-infections)
- Collaborate in regional surveillance activities
 - Regional surveillance is conducted under the authority of the local Medical Health Officer
 - With approval from the local MHO:
 - Provide surveillance data for analysis (line-listed)
 - Conduct analysis of surveillance data on their behalf

Key provincial surveillance objectives

- Describe and monitor the distribution and trends of indicators by age, sex, region, ethnicity, exposure group:
 - New HIV diagnoses
 - Stage of infection (acute, advanced)
 - Co-infections (e.g., HIV/HCV)
- In order to:
 - Provide data for effective prevention programs
 - Support functions of PHO and respond to needs of MHO & designates, FNHA
 - Identify early changes in trends
 - Evaluate the impact and effectiveness of public health programs, inform policy development, guide program planning

Role in STOP HIV/AIDS

- Collaborate with BCCFE on generation of monthly and quarterly indicator reports
- Partner in STOP HIV/AIDS evaluation data linkage initiative
- Provide provincial and regional partners with data/analysis needed for program planning and evaluation
- Conduct analyses of provincial level data to describe and understand trends

Trends in HIV diagnoses





Number of new HIV diagnoses in Other HSDA, 2007 to current (month)



Number of new HIV diagnoses in Vancouver HSDA, 2007 to current (month)

Partnership with PHSA Laboratories (BC PHMRL)

- BC Public Health Microbiology Reference Laboratory
- ~90% of all screening HIV tests, all confirmatory testing
 - Other: Providence Laboratory, Victoria General Hospital Laboratory
- Describe trends in HIV test volumes
 - Age, sex, region, ordering provider or clinic
 - Prenatal vs non-prenatal
- Established use with PHMRL:
 - In aggregate based on age, sex, region
 - For ordering provider or clinic, requires agreement/consent
 - At HA level (STOP leads) for health authority staff or facilities
 - At individual provider level
- Other analyses possible but may need formal data request

Trends in HIV testing

Includes PHMRL, Providence, and Point-of-Care tests



Number of HIV tests done in Northern Interior HSDA, 2007 to current (month)





Trends in Point of care (rapid) HIV tests

Number of POC HIV tests done by Vancouver HSDA, 2010 to current (quarter)



New approaches to case and testing data

- Discussion among STOP pilot partners at beginning of project: what indicators would best reflect program/priorities?
- Measures of testing recommendations & strategies
 - HIV diagnosis and syphilis testing
 - Co-testing for syphilis & HIV
 - HIV testing following STI diagnosis
 - HIV testing following Hepatitis C diagnosis
- Opportunities to revise / consider new indicators
 - First known HIV test at diagnosis
 - Time from last HIV negative to first HIV positive test (inter-test interval)

Testing example: Syphilis test with HIV test same visit



Care example: Syphilis test following HIV diagnosis



Percentage

Lessons learned

- Two way exchange: most useful information coming out of discussion between provincial and regional partners
- Indicators need to be meaningful
 - Need to be valid (measure what they're intended to measure)
 - Need to describe progress towards achieving program goals, are based on program objectives
 - Need to be periodically reviewed, and revised
- Barriers can be overcome
 - Mechanisms for sharing of data (e.g. Providence laboratory data)
 - Develop new capacity for linkage and analysis

Take home messages

- Here to help, and to learn
- Aim to set up efficient process for working with different regional partners
- Point of contact for requests for surveillance and testing data (will facilitate permissions with BC PHMRL if needed) mark.gilbert@bccdc.ca

STOP Program Economic Evaluation

Bohdan Nosyk, PhD CIHR Bisby Fellow MSFHR Career Investigator Research Scientist, Health Economics BC Centre for Excellence in HIV/AIDS







Mathematical Modeling in HIV

- Mathematical modeling:
 - A means of synthesizing information to forecast outcomes over the long term
 - Commonly used to guide policy in HIV
 - UNAIDS HIV Investment Framework
 - US-Based Cost-effectiveness of Preventing AIDS complications (CEPAC) Model
- Health Administrative Databases:
 - Provide detailed population-level data to validate, inform model development







Health Economic Evaluation

- Economic Evaluation Defined:
 - The comparative analysis of alternative courses of action in terms of both their costs and consequences.
- Aim of Economic Evaluation:
 - To inform decisions on how best to allocate available resources to maximize health of population.
- Mathematical Modeling in economic evaluation:
 - Long-term/patient lifetime horizon required to capture all costs and benefits attributable to a given intervention







Inputs into mathematical model

Parameter	Source
HIV Transmission	BC CfE Drug Treatment Program (DTP), published literature
HIV Testing	BC CDC
Disease Progression	BC CfE DTP, BC Vital statistics
Rate of Treatment Entry	BC CFE DTP
Costs of treatment	BC CfE DTP, PharmaNet
Costs of inpatient care	Discharge Abstract Database
Costs of outpatient care	MSP database
Costs of ancillary care	AIMS, HCC, MHS
HRQoL	Peer-Reviewed Literature







Flow diagram of the STOP HIV/AIDS cohort selection process



Nosyk B, Colley G, Yip B, Chan K, et al. (2013) Application and Validation of Case-Finding Algorithms for Identifying Individuals with Human Immunodeficiency Virus from Administrative Data in British Columbia, Canada. PLoS ONE 8(1): e54416. doi:10.1371/journal.pone.0054416 http://www.plosone.org/article/info:doi/10.1371/journal.pone.0054416







Changing costs of HAART



- Quarterly costs stabilized since 2006
- Highest costs attributable to pre-HAART initiators







CD4 Disease Progression during HAART









Quarterly non-HAART Medical Costs



Structure of Mathematical Model



Transitions between states W₁, I₁ and T₁ may occur between transitions in states of disease progression: j -> j+1.







Next Steps: Optimizing Engagement in HIV Care







Summary

- Economic evaluation is about informing decisions on how to focus resources: *Evidence-based decision-making*
- Mathematical modeling is required to make the right long-term decisions
- These models require high-quality data to be valid, useful decision-making tools







Monitoring of the Vancouver STOP HIV/AIDS Pilot Projects

STOP HIV/AIDS Provincial Expansion Knowledge Exchange February 1st 2013

Jat Sandhu PhD

Regional Director Public Health Surveillance Unit Office of the Chief Medical Health Officer Vancouver Coastal Health Authority



VCH Pilot Projects and Activities



Enhanced contact tracing efforts

Monitoring and Evaluation VCH Funded Projects/Activities

Program Level Evaluation

Evaluates activities by each MOU

Developed logic models

Assess short term & long term outcomes

Quantitative and qualitative data

Population Level Monitoring

Evaluates population-level indicators across Vancouver HSDA

Population level datasets from multiple sources

Sophisticated data linkages

Pre – during - post intervention analyses

Allows stratification by important subgroups



Methods

• Monitoring Framework & Indicators

- Indicators developed and approved by STOP Core Team
- Represent phases of the patient journey
- Data Collection and Linkage
 - Data access requests, privacy agreements
 - HIV Public Health Surveillance data
 - BC CfE Drug Treatment Program data
 - Deterministic data linkages
 - Provincial Laboratory HIV testing data
 - VCH/PHC Decision Support
- Pre-During-Post Intervention Analysis
 - Pre: Historical Baseline Period (2008-2009)
 - During: STOP HIV/AIDS (2010-current)

Vancouver • Post: April 2013 onwards

QUARTERLY MONITORING REPORT

HTTP://WWW.VCH.CA/YOUR_HEALTH/DISEASE_SURVEILLANCE/HIV-AIDS/



STOP HIV/AIDS Monitoring Indicators **Quarterly Summary Report** Quarter 3 2012 (July 1 - September 30, 2012)



How you want to be treated.

Indianta	- Norma have		Counts by Quarter			STOP HIV/AIDS (July 1, 2010 to date)			2-year Historical Baseline (Jan 1, 2008 to Dec 31, 2009)			Year to Date Cases		ci	
multator Number		indicator Name	Current Quarter	Apr-Jun 2012	Jan-Mar 2012	Oct-Dec 2011	Avg	Min	Мах	Avg	Min	Мах	Year 2012	Year 2011	Significance
	VCH8a	Overall number of HIV lab tests (either from VCH residents or those who tested at a VCH clinic)	29145	26760	26611	22853	22768	19084	29145	18308	17539	19364	82516	60779	S+H+Y+
	VCH8b	Number of HIV lab tests from all clinics in VCH	27689	25500	25400	21628	21685	18221	27689	17073	16166	18059	78589	58073	S+H+Y+
	VCH8c	Number of HIV lab tests from all Vancouver HSDA clinics	23513	21481	21126	17819	17892	14667	23513	13701	12925	14555	66120	47282	S+H+Y+
IIS	VCH11a	Number of HIV lab tests from residents of VCH (only those with known VCH residence)	18059	17384	17476	15488	14722	12294	18059	11502	10924	12325	52919	39300	S+H+Y+
	VCH11b*	Number of HIV lab tests from residents of Vancouver HSDA	18349	16399	16010	13968	13812	11205	18349	11003	10449	11739	50758	36293	Q+S+H+Y+
Indicato	VCH11c	Number of HIV lab tests from residents of Richmond and Coastal HSDAs	4508	4432	4739	4249	3992	3470	4739	3270	3126	3428	13679	10921	S+H+Y+
esting	VCH11d	Number of HIV lab tests from non- residents of VCH, who tested in VCH	11082	9331	9171	7411	8053	6722	11082	6805	6432	7187	29584	21498	Q+S+H+Y+
F	VCH13a	Number of positive HIV diagnoses for VCH residents	39	33	43	40	41	31	58	44	36	57	115	137	Q+H-Y-
	VCH13b*	Number of positive HIV diagnoses for Vancouver HSDA Residents	34	29	42	36	38	29	51	41	34	54	105	126	Q+H-Y-
	VCH13c	Number of positive HIV diagnoses for Richmond and Coastal HSDAs	5	4	1	4	4	1	7	3	1	6	10	11	Q+S+H+
	VCH14a	Percent positivity (%) of VCH residents	0.22	0.19	0.25	0.26	0.28	0.19	0.42	0.38	0.31	0.52	0.22	0.35	H-Y-
		Percent positivity (%) of Vancouver													

40



Mean monthly rate of HIV lab tests for Vancouver residents per 10,000 population







Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit, November, 2012. Spatial source: BC STATS, BC Ministry of Labour and Citizens' Services.

Population data source: BC STATS, BC Ministry of Labour and Citizens' Services (Population Estimates).

Data source: Provincial Public Health Microbiology and Reference Laboratory (Misys Laboratory Database) & Providence Health Care Virology Laboratory.



Map 3. Since April 2012 to current



Map 2. Since July 2010 to current.





Mean CD4 cell count (cells/mm3) at diagnosis Promoting wellness, Ensuring care, for all HIV positive individuals [VCH45].



Copyright @ 2012 Vancouver Coastal Health, Public Health Surveillance Unit. Not for Commercial Use.



Number of Contacts Notified and Tested for HIV, and Percent Positivity Due to Contact Tracing



How you want to be treated.











Mean community viral load (copies/mL) for all HIV positive individuals



Promoting wellness Ensuring care.

Survey of Healthcare Provider's Attitudes and Perceptions Phase 1 – Prior to Launch of Initiative (n=404)

- 54% agree the incidence of HIV is high enough to justify implementation of routine screening.
- 74% agree detection and treatment of HIV is cost-effective.
- 68% agree HIV testing should be offered to all patients who enter the hospital.
- 62% expressed the need for more education and training to fulfill their role in HIV testing strategy
- Among those not having attended an HIV testing orientation, they are 3 times more likely to strongly disagree with the appropriateness of their workplace setting for HIV testing.
- Among those *having* attended an HIV testing orientation, they are twice as likely to **strongly agree** that HIV fits accepted criteria to justify routine testing and should be part of routine care.







Admission and Testing Proportions by Age Category Before and After the Acute Care Strategy



Males After Acute Care Strategy Before Acute Care Strategy 40% 40% (%) 30% 20% 10% 30% Proportion (%) 20% 10% 0% 0% 0-19 20-29 30-39 40-49 50-59 60-69 70+ 0 - 1920-29 30-39 40-49 50-59 60-69 70+ Age Category Age Category Admission Testing Admission Testing

Females



Note: Period before acute care strategy includes Q3 2010-Q2 2011. Period after acute care strategy includes Q4 2011- Q3-2012. Source: Providence Health Care Virology Laboratory & Vancouver General Hospital Laboratory Database. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. December 6, 2012.

Public Health Surveillance Unit

Progress in Acute Care Testing Initiative

- Up to September 30th 2012:
 - 6,291 HIV tests have been conducted among admitted patients (13% of all admissions)
 - 1 new positive for every 274 tests (overall percent positivity of 0.4%)
- Characteristics of those diagnosed:
 - $-\uparrow$ Heterosexual, \downarrow MSM exposure risk factors
 - $-\uparrow$ Advanced stage of disease
 - − \downarrow Mean CD4 (Δ 193 cells per mm³; 95% CI 88 299, p<0.001)



Acknowledgements

- Microbiology & Virology at Providence Health Care Willson Jang, Technical Leader
- Public Health Microbiology and Reference Laboratory Yin Chang, Laboratory Surveillance and Outbreak Coordinator & Rob MacDougall, Laboratory Information Management Coordinator
- Vancouver Coastal Health STOP Outreach Team Meaghan Thumath, Clinical Practice Initiatives Lead and the STOP Outreach Team
- BC Centre for Excellence in HIV/AIDS Benita Yip & William Chau, Analysts and Dr. Kate Heath, Epidemiologist
- Vancouver Coastal Health Communicable Disease Control Margot Smythe, Communicable Disease Nurse Educator; Logan Chinski, HIV Communicable Disease Control Nurse & the Communicable Disease Control Nurses
- Vancouver Coastal Health STOP HIV/AIDS Core Project Team



Public Health Surveillance Unit

Supporting regional public health practice:

- Health Assessment
- Disease Surveillance
- Epidemiological Investigations
- Knowledge Transfer

Public Health Surveillance Unit

8th Floor - 601 West Broadway Vancouver, British Columbia Canada V5Z 4C2



phsu@vch.ca

Monitoring and Evaluation at a Population Level

How monitoring and evaluation supported the initiative

Dr. Réka Gustafson



How did monitoring and evaluation make a difference?

- Kept us focused on testing and treatment
- Helped define where we started
- Helped define where we were going
- Showed us if we were getting there
- If not, helped us define why we were not



Where are we?



Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. December 22, 2011.

Why are we here?

Percent & proportion of new HIV diagnoses with ≥1 prior Outpatient, Lab, ER or Inpatient encounter, by CD4 count

CD4 Count*	≥ 1 prior encounter
< 200	58% (30/52)
< 350	60% (64/107)
< 500	55% (97/177)

* Only 57.5% (291/506) of new HIV Dx had a CD4 count on record at time of Dx



Are we getting there?

STOP HIV/AIDS VANCOUVER



Date



STOP HIV/AIDS VANCOUVER If we are not getting there, why not?

Department of Medicine: October 2011 – December 30, 2012

Site	Number of Admissions	Number Offered	Number Tested	Acceptance Rate	% Offered	% Tested	Number of Positives	Positivity Rate per 1000
SPH	3769	1717	1439	97%	46%	38%	11	~ 8/1000
MSJ	1644	1051	781	85%	64%	48%	3	~ 4/1000
VGH	4689	1590	1270	96%	34%	27%	4	~ 3/1000
Total	10102	4358	3490	94%	43%	35%	18	~ 5/1000



What got us there?



Where is it working?

C	Duran anti-	Demonst	
Positive Positivity			
Acute Care: Provider -	25 total	TBD	
Initiated	(14/2,496) Dept of Med	0.6% (approx. from Dept of Medicine)	
Acute Care:			
Patient - Initiated	22/1,216	1.8%	

Routine testing cost-effectiveness threshold: 1 positive per 1,000 tests¹

¹Qaseem, A., Snow, V., Shekelle, P. et al. (2009). Screening for HIV in health care settings: A guidance statement from the American College of Physicians and HIV Medicine Association. *Ann Intern Med* <u>150</u>:125-131.



What is the population level impact?





CoastalHealth

Is it making a difference in my neighbourhood?



Testing

Vancouver CoastalHealth Promoting wellness. Ensuring core.

Mean monthly rate of HIV lab tests for Vancouver residents per 10,000 population [VCH11c].



Map 2. Vancouver local health areas, since STOP HIV/AIDS July 1, 2010 to current.



Diagnosis



Mean CD4 cell count (cells/mm3) at diagnosis for all HIV positive individuals [VCH45].



Copyright (0 2012 Vancouver Coastal Health, Public Health Surveillance Unit. Not for Commercial Use

Treatment



Mean community viral load (copies/mL) for all HIV positive individuals [VCH53]



Keeping momentum



MEMORANDUM

TO:	SPH & MSJ LEADERSHIP
FROM:	DR. RON CARERE
SUBJECT:	HIV TESTING – UPDATED RESULTS
DATE:	NOV 9, 2012
CC:	REKA GUSTAFSON, SCOTT HARRISON, CHRIS BUCHNER, TIFFANY AKINS, ARTHUR YEE, AFSHAN NATHOO

Dear colleagues,

Please find below the most recent results from the Routine HIV Testing in Acute Care Initiative. Routinely offering HIV tests is highly acceptable to patients, with 94% of patients accepting the test when offered during hospital admission (i.e. # refused/# offered). In addition, the number of new diagnoses from routine acute care screening is well above what we expected and well above the cost-effectiveness threshold for routine HIV screening programs. Please share these results with your colleagues.

To date, 3,092 tests have been completed and 18 new diagnoses have been discovered within the Departments of Medicine at SPH, MSJ and VGH, which translates to <u>6-times</u> the costeffectiveness threshold for routine HIV testing. Overall, 21 diagnoses have been made within all departments at SPH and MSJ alone.

Table 1 Department of Medicine Chart Audit Data: October 2011 - November 4, 2012

Site	Number of Admissions	Number Offered	Number Tested	Acceptance Rate	% Offered	% Tested	Number of Positives	Positivity Rate per 1000
SPH	3396	1544	1294	97%	45%	38%	11	~ 9/1000
MSJ	1438	941	688	85%	65%	48%	3	~ 4/1000
VGH	4244	1429	1110	96%	34%	26%	4	~ 4/1000
Total	9078	3914	3092	94%	43%	34%	18	~ 6/1000

Table 2 PHC Acute Care Cases by Department: October 2011 – November 4, 2012

	SPH Medicine	SPH ED	SPH Surgery	SPH Renal	SPH Psychiatry	SPH Gyne	MSJ Medicine	MSJ Surgery	Total
Cases	11	5	0	0	1	1	3	0	21

Thank you for your continued support of the STOP HIV/AIDS Project. Our team will continue to keep you updated. To protect patient confidentiality, please do not forward this information to anyone outside VCH or PHC.



Did I really change my practice?

Dr. XXX (99999) HIV Testing Summary

HIV test Summary 2011 - current*	2011	2012 Year to date (to Aug 31, 2012)	2012 Month of August
Total HIV tests processed	70	65	10
Monthly average	5.8	8.1	





Summary

- Data to engage the community, leaders and providers
- Data to evaluate progress and change direction if needed
- Data to monitor the project overall
- Data to maintain momentum
- Data to celebrate success

